Rho: 'The hurdles are high when you have a drug that the world doesn’t need'

By Melissa Fassbender contact

- Last updated on GMT

Related tags: Rho, Quality by design, Regulations, Patient recruitment

Rho experts speak to the challenges facing drug development, meeting unmet needs, quality by design, and advances in technology, among other topics, during a sit-down at the CRO’s headquarters.

Today, it’s more difficult to develop a new medication that meets an unmet need, as products are more effective and safer than in the past, explained Jack Modell, MD, vice president and senior medical officer, Rho.

“It gets difficult with drug development because there are still a lot of unmet needs, a lot of opportunities, but they are harder to find, and the hurdles are higher because we’ve got better medications,”​ said Modell. “Therefore, the trials tend to be longer, larger, more expensive, and the regulatory hurdles even higher as well.”

The industry also struggles with clinical trial recruitment and ‘not getting the right patients,’ he said, noting the presence of ‘professional patients,’ among other challenges.

As one way to address this, Modell suggested the use of computerized assessments, such as interactive voice response. “For some things, computers are better than people,”​ he said during a discussion with Outsourcing-Pharma and colleague, Matt Healy, Rho vice president of clinical operations, at the company’s headquarters in Durham, NC.

“We’re at a point in time now where things are progressing faster than they ever have before,”​ said Healy, who cited the advent of technology and changes in guidances as key to this acceleration.

“The hurdles are high when you have a drug that the world doesn’t need,”​ added Modell. “But when you have a drug that the world needs and is waiting for … FDA and everybody else will do what they can to help get that drug approved.”

For the full conversation, watch the video above.

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars